UPDATE 1-Gilead hepatitis C drug sales beat estimates, boosts dividend
February 02, 2016 at 17:04 PM EST
LOS ANGELES, Feb 2 (Reuters) - Gilead Sciences Inc's hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected.
